In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

What effect will the tariffs have on drug pricing and patient access? Arda Ural: Over the last 20 years, our industry has taken advantage of the global, integrated economy. The vast majority of global ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...